Submit an abstract to the Inaugural Canadian Gene and Cell Therapy Conference by October 1! For more information or to submit an abstract, visit cancgt.ca.

📢 We're less than one week away from the 2026 Policy Summit! Register now ➡️ https://bit.ly/4wIMIem #ASGCTadvocacy #PS26

The FDA has approved Genglycos, an AAV gene therapy developed by Ultragenyx Pharmaceuticals. Read our full blog post about the approval here: https://bit.ly/3SbpDlN

FDA Approves Genglycos, First Gene Therapy for GSDIa

The unbiased source for reliable, scientific information, news, and breakthroughs in gene and cell therapy.

bit.ly

📰 Our latest edition of The Patient Press newsletter is now available! This month, read updates about OMB, check out our two new Patient Education resources, catch up on our recent Congressional Briefing on CGT for Rare Disease, and more. Read The Patient Press now ➡️ https://bit.ly/4il1BiC

🎙️ Meet Anna Maurer, PhD in our newest episode of Scientists, Unedited. Recorded live at the 2026 Annual Meeting in Boston, host Eirini Vamva, PhD talks with Dr. Maurer about growing up in Michigan, studying at Harvard Medical School, and her work in AAV. Listen now! ➡️ https://bit.ly/44O6hpt

bit.ly

Hear from leading minds in oncology at this fully virtual event! Join us Oct 14-15 to learn about the innovative approaches reshaping cancer treatment while addressing the critical challenges currently facing the field. Register now ➡️ https://bit.ly/4aX9OVW

From blood cancers to autoimmune diseases, CAR T-cell therapy is expanding far beyond its original boundaries. Start learning in our latest content collection: https://learning.asgct.org/courses/238146

A new stage for Breakthroughs: Join us in Nashville! Customize your experience across three concurrent tracks covering translation & manufacturing, biological precision, and the new therapeutic architectures overcoming challenges in the central nervous system: asgct.org/breakthroughs

ASGCT's advocacy on OMB's proposed Uniform Guidance reforms continues. This month, the Society submitted comments urging OMB to withdraw the rule, led a coalition letter to Congress, and launched grassroots outreach to protect #CGT research. Read more: https://bit.ly/4voQvvR #ASGCTAdvocacy

The Advocate: July 2026

ASGCT's advocacy on OMB's proposed Uniform Guidance reforms continues. This month, the Society submitted comments urging OMB to withdraw the rule, led a…

asgct.org

Fyodor Urnov, 2026 ASGCT Catalyst Award co-recipient, joins this episode of The Issue to discuss the rapid evolution of gene-editing technology and the critical role of industry-wide collaboration in bringing life-changing therapies to patients. 🎧 Listen: https://bit.ly/4h8nDob

How is innovation advancing cell and gene therapy manufacturing? Read our #ASGCT2026 recap on how automation, analytics, and regulatory readiness are shaping the future of CGT development: https://bit.ly/4aXWNLV

Advancing CGT Manufacturing and Regulation Through Innovation and…

At ASGCT’s 2026 Annual Meeting, leaders from the FDA, industry, and academia came together to discuss technologies and regulatory approaches shaping the…

bit.ly

Level up your cell and gene therapy experience in just one day! Dive into real-world applications of AAV, CAR T, and HSC modalities, clinical management of toxicities, and the future of individualized medicine at this focused, one-day event at @nationwidekids.bsky.social! Details: asgct.org/gme

Looking for a community that supports your career and keeps you connected to the latest in the field? Join ASGCT this summer and save up to 15% on your dues! asgct.org/become-a-member

These $100K awards provide vital financial and professional development support to postdoctoral or early-career members from groups that have historically faced limited access to research opportunities, mentorship, or career advancement resources in science. asgct.org/expanding

Expanding Pathways Fellowship

These awards are designed for postdoctoral or early-career members from groups that have historically faced limited access to career advancement in…

asgct.org

FDA approved Tregzi, an allogeneic cell therapy using Tregs to reduce complications of allo-HSCTs. This approval is an important advancement for patients with blood cancers. ASGCT President Dr. Matt Porteus shares what this approval means for the #CGT field: https://bit.ly/44RGgW0

FDA Approves Allogenic Immunotherapy for Blood Cancers with Reduced...

This approval represents an important advancement for patients with blood cancers, demonstrating the potential to improve the safety and effectiveness of...

asgct.org

The ASGCT Policy Summit is uniquely designed to break down silos and spark real collaboration with the stakeholders driving the future of cell and gene therapy policy. Join us September 14 in Washington, D.C., or online: asgct.org/policysummit

Recorded live at #ASGCT2026, listen as Molecular Therapy Advances Editor-in-Chief Dr. Mohamed Abou-el-Enein sits down with Drs. Jennifer Adair, Claire Booth, Terence Flotte, and Donald Kohn to discuss the evolving landscape of rare disease therapies: https://bit.ly/4v6eHDj

Applications are open for the ASGCT Career Development Awards, offering vital financial support to early-career scientists and postdocs driving innovation in the field. Don't miss the chance to fund your research and grow your network. Apply today: asgct.org/cda

The latest Patient Press is here! Catch up on crucial updates on proposed federal grant changes, our brand-new cell and gene therapy coloring book, a new Community Quick Take, and the latest clinical trial breakthroughs in rare disease research. https://bit.ly/4gdItSK

The Patient Press: June 2026

We're breaking down how the OMB Proposed Rule affects medical research and future treatments. Plus, check out our new coloring book and the latest patient…

patienteducation.asgct.org

Biomedical innovation depends on stable research funding. We're leading a sign-on letter opposing proposed OMB changes that could slow progress in #CGTs. Organizations can sign by July 15 at 12 p.m. ET. 🔗 Sign here: https://bit.ly/4gdQ8AA

FDA approval is only the first step in bringing cell and gene therapies to patients. At #ASGCT2026, experts explored the challenges that continue to limit patient access and how value-based payment models and cross-sector collaboration can help build more sustainable pathways. https://bit.ly/4yciBNR

Building Sustainable Access Pathways for Cell and Gene Therapies

As more cell and gene therapies (CGTs) move from development into clinical practice, stakeholders across the healthcare system are increasingly…

asgct.org

As we kick off our 2027 awards cycle, we invite you to take a moment to nominate your colleagues, mentors, mentees, and fellow collaborators for an ASGCT Honorific Award! https://bit.ly/4aE0A0L

Behind Every Award is a Nomination: ASGCT is Now Accepting…

As we kick off our 2027 awards cycle, we invite you to take a moment to nominate your colleagues, mentors, mentees, and fellow collaborators for an ASGCT…

asgct.org

What does the path to leadership in cell and gene therapy look like? Scientists, Unedited host Eirini Vamva, PhD, sits down with ASGCT President Matthew Porteus, PhD, for a candid conversation about his journey, motivations, and life beyond the lab. 🎧 Listen: https://bit.ly/4uZYFea

In rare disease research, traditional clinical trials aren't always possible. Check out this Community Quick Take to learn how patient data is helping researchers go beyond the placebo control and accelerate life-changing treatments. ▶️ Watch now: https://bit.ly/4fLiguF

📢 Registration and abstract submissions are officially open for Breakthroughs in Cell & Gene Therapy! Explore our 2026 program tracks, view abstract categories, and secure your spot today: asgct.org/breakthroughs

From dreaming about genetics since high school in Nigeria to tackling the field's biggest immune challenges as a University of Missouri PhD candidate, Godwin Iroanya's journey is all about making the "impossible" possible. Listen now: https://bit.ly/4ewfqaB

#WorldSickleCellDay reminds us of the critical importance of advancing awareness, fostering connection, and driving equitable progress for every individual and family impacted by SCD. ❤️ Hear from sickle cell warriors in this session from the 2026 Empowering Patients Summit: https://bit.ly/4os6ojo

How are patient-centered approaches shaping the future of cell and gene therapy development? Check out the key takeaways from our recent Annual Meeting symposia on aligning patient experience, regulatory strategy, and clinical trial design. Read the full recap: https://bit.ly/4vKIt18

Patient-Centered Innovation in Rare Disease CGTs at ASGCT 2026 Annual…

Across both symposia, a consistent message emerged: advancing cell and gene therapies for rare diseases requires continued evolution in how patients are…

asgct.org

Bringing a cell or gene therapy from concept to patient requires more than great science. The 2026 ASGCT Policy Summit dives into the full arc of CGT development, from pipeline funding and regulatory strategy through manufacturing, payment policy, and patient access. Join us:: asgct.org/policysummit

Get to know the new co-hosts, Jason West, PhD, and Sanjay D’Souza, PhD, as they share their backgrounds, ask each other questions, and share how listeners can get involved with future content of The Issue podcast. 🎧 Listen now: https://bit.ly/4vUjSXA